Abstract:Background: Modern experimental techniques deliver data sets containing profiles of tens of thousands of potential molecular and genetic markers that can be used to improve medical diagnostics. Previous studies performed with three different experimental methods for the same set of neuroblastoma patients create opportunity to examine whether augmenting gene expression profiles with information on copy number variation can lead to improved predictions of patients survival. We propose methodology based on comprehensive cross-validation protocol, that includes feature selection within cross-validation loop and classification using machine learning. We also test dependence of results on the feature selection process using four different feature selection methods. Results: The models utilising features selected based on information entropy are slightly, but significantly, better than those using features obtained with t-test. The synergy between data on genetic variation and gene expression is possible, but not confirmed. A slight, but statistically significant, increase of the predictive power of machine learning models has been observed for models built on combined data sets. It was found while using both out of bag estimate and in cross-validation performed on a single set of variables. However, the improvement was smaller and non-significant when models were built within full cross-validation procedure that included feature selection within cross-validation loop. Good correlation between performance of the models in the internal and external cross-validation was observed, confirming the robustness of the proposed protocol and results. Conclusions: We have developed a protocol for building predictive machine learning models. The protocol can provide robust estimates of the model performance on unseen data. It is particularly well-suited for small data sets. We have applied this protocol to develop prognostic models for neuroblastoma, using data on copy number variation and gene expression. We have shown that combining these two sources of information may increase the quality of the models. Nevertheless, the increase is small and larger samples are required to reduce noise and bias arising due to overfitting. Reviewers: This article was reviewed by Lan Hu, Tim Beissbarth and Dimitar Vassilev.

Publisher Correction: Genetic co-expression networks contribute to creating predictive model and exploring novel biomarkers for the prognosis of breast cancer

Correction To: Analysis of Dynamic Molecular Networks for Pancreatic Ductal Adenocarcinoma Progression

Corrigendum: Hypoxia-Associated Prognostic Markers and Competing Endogenous RNA Co-Expression Networks in Breast Cancer

A Novel Coiled-Coil Domain Containing-Related Gene Signature for Predicting Prognosis and Treatment Effect of Breast Cancer.

Corrigendum: A Prognostic Model Based on Immune-Related Long Non-Coding RNAs for Patients With Cervical Cancer

Publisher Correction: A Clonal Expression Biomarker Associates with Lung Cancer Mortality

Correction: Corrigendum: Identification of High-Quality Cancer Prognostic Markers and Metastasis Network Modules

Publisher Correction: Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors

Novel Model for Comprehensive Assessment of Robust Prognostic Gene Signature in Ovarian Cancer Across Different Independent Datasets

Publisher Correction: Shared heritability and functional enrichment across six solid cancers

Tumor Microenvironment-Related Multigene Prognostic Prediction Model for Breast Cancer

Protein interaction network underpins concordant prognosis among heterogeneous breast cancer signatures

Corrigendum: Identification of Signature Genes Associated With Invasiveness and the Construction of a Prognostic Model That Predicts the Overall Survival of Bladder Cancer

An Improved Method for Prediction of Cancer Prognosis by Network Learning

Corrigendum: Immune regulation and prognostic prediction model establishment and validation of PSMB6 in lung adenocarcinoma

Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures

Corrigendum: Identification and validation of immune-related methylation clusters for predicting immune activity and prognosis in breast cancer

Corrigendum: Immunogenomic landscape in breast cancer reveals immunotherapeutically relevant gene signatures

Integration of multiple types of genetic markers for neuroblastoma may contribute to improved prediction of the overall survival

Identification and Validation of a Novel Prognosis Prediction Model in Adrenocortical Carcinoma by Integrative Bioinformatics Analysis, Statistics, and Machine Learning

Integrated Multi-Omics Analysis Model to Identify Biomarkers Associated With Prognosis of Breast Cancer